Figure 2.

Box plots of ADJUNCT ONE completers (dark blue) vs ADJUNCT ONE non-completers (light blue) and for ADJUNCT TWO completers (dark green) and ADJUNCT TWO non-completers (light green) for body weight (A), BMI (B), age (C), duration of T1D (D), CSII—total daily insulin dose (E), MDI—total daily insulin dose, (F). Data were combined across all three liraglutide dose groups (1.8 mg, 1.2 mg, and 0.6 mg) and placebo. Lower and upper bounds of the boxes denote 25th and 75th percentiles of the data sets and the line inside the box denotes the median value (50th percentile). The whiskers mark the 10th and 90th percentiles, respectively. Values beyond these lower and upper bounds are denoted by individual dots. Proportion of C-peptide below the LLOQ is presented as a bar plot (G).

Statistically significant differences for non-completers vs completers within each of the ADJUNCT studies added according to: *P < .05, **P < .01, ***P < .001, ****P < .0001. No statistical analysis was possible to perform for the C-peptide proportion as this was a single digit.

Abbreviations: BMI, body mass index; CSII, continuous subcutaneous insulin infusions; LLOQ, lower level of quantification; MDI, multiple daily insulin injections; SD, standard deviation; T1D, type 1 diabetes.